-
公开(公告)号：US20050118226A1
公开(公告)日：2005-06-02
申请号：US10983969
申请日：2004-11-08
申请人： Dora Kovacs , Luigi Puglielli , Rudolph Tanzi , Matthew Frosch
发明人： Dora Kovacs , Luigi Puglielli , Rudolph Tanzi , Matthew Frosch
IPC分类号： A61K9/00 , A61K31/4965 , A61K9/22
CPC分类号： A61K9/0024 , A61K31/4965
摘要： The invention relates to methods for administering inhibitors of acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity, and for treating Alzheimer's disease, atherosclerosis, and other ACAT-related diseases. The invention also relates to sustained release delivery systems.
摘要翻译： 本发明涉及施用酰基辅酶A：胆固醇酰基转移酶（ACAT）活性抑制剂和治疗阿尔茨海默氏病，动脉粥样硬化和其它ACAT相关疾病的方法。 本发明还涉及持续释放递送系统。
-
2.发明申请Methods and compositions relating to modulating amyloid precursor protein cleavage 审中-公开涉及调节淀粉样蛋白前体蛋白切割的方法和组合物公开(公告)号：US20050170437A1
公开(公告)日：2005-08-04
申请号：US10984017
申请日：2004-11-08
CPC分类号： G01N33/6896 , C12Q1/37 , C12Q1/48 , G01N2333/4709 , G01N2333/91057 , G01N2500/00 , G01N2800/2821
摘要： The invention relates in part assays for identifying and testing compounds that modulate cleavage of amyloid precursor protein (APP). In addition, the invention relates to novel cleavage products of APP. The invention additionally relates to methods and assays for identifying compounds that inhibit acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity. The methods and products of the invention are useful for identifying compounds to prevent and/or treat APP-cleavage associated disorders (e.g. Alzheimer's disease) and are also useful for identifying compounds to prevent and/or treat ACAT-associated disorders.
摘要翻译： 本发明涉及用于鉴定和测试调节淀粉样前体蛋白（APP）切割的化合物的部分测定法。 此外，本发明涉及APP的新型切割产物。 本发明还涉及用于鉴定抑制酰基辅酶A：胆固醇酰基转移酶（ACAT）活性的化合物的方法和测定法。 本发明的方法和产品可用于鉴定化合物以预防和/或治疗APP-切割相关疾病（例如阿尔茨海默氏病），并且也可用于鉴定预防和/或治疗ACAT相关疾病的化合物。
-
公开(公告)号：US20120329789A1
公开(公告)日：2012-12-27
申请号：US13484725
申请日：2012-05-31
申请人： Luigi Puglielli
发明人： Luigi Puglielli
IPC分类号： A61K31/538 , A61K31/136 , A61P25/28 , A61K31/498
CPC分类号： A61K31/136 , A61K31/00 , A61K31/137 , A61K31/496 , A61K31/498 , A61K31/538
摘要： Pharmaceutical compositions for treating Alzheimer's disease are disclosed. The pharmaceutical compositions include a compound having the general formula: and a pharmaceutically acceptable carrier. Methods for treating Alzheimer's disease, inhibiting ATase I and/or ATase 2, reducing the activity of BACE1, reducing the level of amyloid β-peptide (Aβ), and/or reducing the level of APP intracellular domain peptide (AICD) by administering such compositions are also disclosed.
摘要翻译： 公开了用于治疗阿尔茨海默氏病的药物组合物。 药物组合物包括具有以下通式的化合物：和药学上可接受的载体。 用于治疗阿尔茨海默病的方法，抑制ATase I和/或ATase 2，降低BACE1的活性，降低淀粉样蛋白和蛋白的水平（A＆bgr），和/或降低APP细胞内结构域肽（AICD）的水平 还公开了这些组合物的施用。
-
公开(公告)号：US08980884B2
公开(公告)日：2015-03-17
申请号：US13484725
申请日：2012-05-31
申请人： Luigi Puglielli
发明人： Luigi Puglielli
IPC分类号： A61K31/535 , A61K31/50 , A61K31/00 , A61K31/136 , A61K31/498 , A61K31/538 , A61K31/496
CPC分类号： A61K31/136 , A61K31/00 , A61K31/137 , A61K31/496 , A61K31/498 , A61K31/538
摘要： Pharmaceutical compositions for treating Alzheimer's disease are disclosed. The pharmaceutical compositions include a compound having the general formula: and a pharmaceutically acceptable carrier. Methods for treating Alzheimer's disease, inhibiting ATase I and/or ATase 2, reducing the activity of BACE1, reducing the level of amyloid β-peptide (Aβ), and/or reducing the level of APP intracellular domain peptide (AICD) by administering such compositions are also disclosed.
摘要翻译： 公开了用于治疗阿尔茨海默氏病的药物组合物。 药物组合物包括具有以下通式的化合物：和药学上可接受的载体。 用于治疗阿尔茨海默病的方法，抑制ATase I和/或ATase 2，降低BACE1的活性，降低淀粉样蛋白和蛋白的水平（A＆bgr），和/或降低APP细胞内结构域肽（AICD）的水平 还公开了这些组合物的施用。
-
公开(公告)号：US20090042993A1
公开(公告)日：2009-02-12
申请号：US12099378
申请日：2008-04-08
申请人： Luigi Puglielli
发明人： Luigi Puglielli
IPC分类号： A61K31/164 , C12Q1/37 , A61P25/00 , A01K67/027
CPC分类号： G01N33/5008 , A01K2267/0312 , C12Q1/37 , C12Q1/48 , G01N33/5076 , G01N33/68
摘要： Compositions and methods for post-translational modifications that include protein acetylation in the ER lumen and deacetylation in the Golgi apparatus are provided. The disclosed methods are especially suited for the identification of compounds useful for the prevention or treatment of neurodegenerative diseases such as Alzheimer's.
摘要翻译： 提供了包括ER腔中的蛋白质乙酰化和高尔基体中脱乙酰化的翻译后修饰的组合物和方法。 所公开的方法特别适用于鉴定可用于预防或治疗神经变性疾病如阿尔茨海默病的化合物。
-
公开(公告)号：US20090136977A1
公开(公告)日：2009-05-28
申请号：US12263138
申请日：2008-10-31
申请人： Luigi Puglielli
发明人： Luigi Puglielli
CPC分类号： C12Q1/48 , G01N2500/04
摘要： Compositions and methods for post-translational modifications that include acetylCoA:lysine acetyltransferase activity in the ER lumen are provided. The disclosed compositions and methods are especially suited for the identification of compounds useful for the prevention or treatment of neurodegenerative diseases such as Alzheimer's.
摘要翻译： 提供了在ER腔中包括乙酰CoA：赖氨酸乙酰转移酶活性的翻译后修饰的组合物和方法。 所公开的组合物和方法特别适用于鉴定可用于预防或治疗神经变性疾病如阿尔茨海默病的化合物。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.021 秒)